Format

Send to

Choose Destination
Methods Mol Biol. 2014;1139:337-44. doi: 10.1007/978-1-4939-0345-0_27.

TLR-9 agonist immunostimulatory sequence adjuvants linked to cancer antigens.

Author information

1
Department of Clinical Oncology, Tohoku University, Sendai, Japan.

Abstract

The primary goal of cancer vaccines is to elicit tumor-specific cytotoxic T lymphocytes (CTL) capable of eradicating established tumors and preventing/eradicating their metastatic spread. CpG oligonucleotides (CpG ODN) activate and support the maturation of immune cells, including plasmacytoid dendritic cells and B lymphocytes, that express Toll-like receptor 9 (TLR9) and are capable of presenting tumor antigens to T cells. Thus, CpG ODN are effective vaccine adjuvants. The adjuvant activity of CpG ODN is improved by maintaining them in close physical and temporal proximity to the co-administered vaccine antigen. This work describes a method of chemically conjugating CpG ODN to antigens and/or cancer cells that improve the resulting CTL response.

PMID:
24619691
PMCID:
PMC6457254
DOI:
10.1007/978-1-4939-0345-0_27
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center